At this time, the proportion of GFP+ T‐ALL cells in the bone marrow of both Irf8−/− and Irf8+/+ groups without FB23‐2 treatment had reached peaks (Figure S2A, Supporting Information). The gene discussed is IRF8; the disease is acute lymphoblastic leukemia.